A recent study shows that, like cancer cells, cells lacking the Pdk1 gene reprogram their metabolism to use aerobic glycolysis—the 'Warburg effect'. Targeting this pathway using a glucose analog that cannot be metabolized resulted in slower disease progression in mouse models of polycystic kidney disease. This work thus suggests a new potential therapeutic approach for autosomal dominant polycystic kidney disease (pages 488–493).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion
Nature Communications Open Access 30 March 2023
-
Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways
Communications Biology Open Access 16 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grantham, J.J. Am. J. Kidney Dis. 15, 110–116 (1990).
Harris, P.C. & Watson, M.L. Nephrol. Dial. Transplant. 12, 1089–1090 (1997).
Qian, F., Watnick, T.J., Onuchic, L.F. & Germino, G.G. Cell 87, 979–987 (1996).
Brasier, J.L. & Henske, E.P. J. Clin. Invest. 99, 194–199 (1997).
Henske, E.P. & McCormack, F.X. J. Clin. Invest. 122, 3807–3816 (2012).
Hanahan, D. & Weinberg, R.A. Cell 100, 57–70 (2000).
Nadasdy, T. et al. J. Am. Soc. Nephrol. 5, 1462–1468 (1995).
Huang, J.L., Woolf, A.S. & Long, D.A. Pediatr. Nephrol. published online, doi:10.1007/s00467-012-2305-7 (19 September 2012).
Wilson, P.D. Biochim. Biophys. Acta 1812, 1239–1248 (2011).
Hanahan, D. & Weinberg, R.A. Cell 144, 646–674 (2011).
Rowe, I. et al. Nat. Med. 19, 488–493 (2013).
Warburg, O. Science 123, 309–314 (1956).
Parkhitko, A. et al. Proc. Natl. Acad. Sci. USA 108, 12455–12460 (2011).
Vander Heiden, M.G. Nat. Rev. Drug Discov. 10, 671–684 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Priolo, C., Henske, E. Metabolic reprogramming in polycystic kidney disease. Nat Med 19, 407–409 (2013). https://doi.org/10.1038/nm.3140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3140
This article is cited by
-
The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion
Nature Communications (2023)
-
ADPKD current management and ongoing trials
Journal of Nephrology (2020)
-
Echogenic Kidneys as an Antenatal Clue to the Metabolic Etiology: A Case Report
Journal of Fetal Medicine (2019)
-
Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways
Communications Biology (2018)
-
Metabolism and mitochondria in polycystic kidney disease research and therapy
Nature Reviews Nephrology (2018)